Randomized Trialhigh evidence
Mazdutide versus placebo in Chinese adults with type 2 diabetes.
Nature·April 1, 2026·PMID 41407859
Why it mattersFor clinicians managing early type 2 diabetes with concurrent excess weight, this trial suggests mazdutide may offer meaningful dual glycemic and weight benefit as monotherapy. It is relevant when considering incretin-based options that target both hyperglycemia and obesity-related metabolic burden.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled